Literature DB >> 31784900

[Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

U Kiltz1, J Braun2, A Becker3, J-F Chenot4, M Dreimann5, L Hammel6, A Heiligenhaus7, K-G Hermann8, R Klett9, D Krause10, K-F Kreitner11, U Lange12, A Lauterbach13, W Mau14, R Mössner15, U Oberschelp16, S Philipp17, U Pleyer18, M Rudwaleit19, E Schneider20, T L Schulte21, J Sieper22, A Stallmach23, B Swoboda24, M Winking25.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31784900     DOI： 10.1007/s00393-019-0670-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  594 in total

Review 1.  Mortality in rheumatoid arthritis and ankylosing spondylitis.

Authors:  J Zochling; J Braun
Journal:  Clin Exp Rheumatol       Date:  2009 Jul-Aug       Impact factor: 4.473

2.  [Rehabilitation in axial spondyloarthritides].

Authors:  W Mau; I Ehlebracht-König
Journal:  Rehabilitation (Stuttg)       Date:  2013-02-13       Impact factor: 1.113

3.  Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis.

Authors:  Denis Poddubnyy; Hildrun Haibel; Joachim Listing; Elisabeth Märker-Hermann; Henning Zeidler; Jürgen Braun; Joachim Sieper; Martin Rudwaleit
Journal:  Arthritis Rheum       Date:  2012-05

4.  Risk of falls in patients with ankylosing spondylitis.

Authors:  Nigar Dursun; Selda Sarkaya; Senay Ozdolap; Erbil Dursun; Coskun Zateri; Lale Altan; Murat Birtane; Kenan Akgun; Aylin Revzani; İlknur Aktas; Nurettin Tastekin; Reyhan Celiker
Journal:  J Clin Rheumatol       Date:  2015-03       Impact factor: 3.517

5.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Authors:  S Garrett; T Jenkinson; L G Kennedy; H Whitelock; P Gaisford; A Calin
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

6.  Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation.

Authors:  E K Li; J F Griffith; V W Lee; Y-X Wang; T K Li; K K Lee; L-S Tam
Journal:  Rheumatology (Oxford)       Date:  2008-06-23       Impact factor: 7.580

7.  Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.

Authors:  Irene E van der Horst-Bruinsma; Debra Jeske Zack; Annette Szumski; Andrew S Koenig
Journal:  Ann Rheum Dis       Date:  2012-12-22       Impact factor: 19.103

8.  Sponyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort.

Authors:  Victoria Navarro-Compán; Eugenio de Miguel; Désirée van der Heijde; Robert Landewé; Raquel Almodóvar; Carlos Montilla; Emma Beltrán; Pedro Zarco
Journal:  Arthritis Res Ther       Date:  2015-09-23       Impact factor: 5.156

9.  Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.

Authors:  Alexandre Sepriano; Andrea Regel; Désirée van der Heijde; Jürgen Braun; Xenofon Baraliakos; Robert Landewé; Filip Van den Bosch; Louise Falzon; Sofia Ramiro
Journal:  RMD Open       Date:  2017-01-27

10.  Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.

Authors:  D van der Heijde; A L Pangan; M H Schiff; J Braun; M Borofsky; J Torre; J C Davis; R L Wong; H Kupper; E Collantes
Journal:  Ann Rheum Dis       Date:  2007-12-04       Impact factor: 19.103
View more
  5 in total

1.  [Sports and exercise therapy in inflammatory rheumatic diseases].

Authors:  Wolfgang Hartung; Philipp Sewerin; Benedikt Ostendorf
Journal:  Z Rheumatol       Date:  2021-03-08       Impact factor: 1.372

Review 2.  [Multimodal rheumatological complex treatment : A current inventory].

Authors:  Philipp Klemm; Ulf Müller-Ladner; Uwe Lange
Journal:  Z Rheumatol       Date:  2022-03-29       Impact factor: 1.372

3.  [Apps in rheumatology : Is there a need for an app in therapy for axial spondyloarthritis?]

Authors:  Patrick-Pascal Strunz; Maxime Le Maire; Tobias Heusinger; Ludwig Hammel; Michael Gernert; Eva C Schwaneck; Johanna Callhoff; Jan Portegys; Marc Schmalzing; Hans-Peter Tony; Matthias Froehlich
Journal:  Z Rheumatol       Date:  2021-10-07       Impact factor: 1.372

4.  [Update: enterogenic spondylarthritis].

Authors:  Elisabeth Märker-Hermann
Journal:  Z Rheumatol       Date:  2021-05-27       Impact factor: 1.372

Review 5.  [Rheumatology in German MD curricula].

Authors:  M Aringer; C Baerwald; R Bergner; M Feuchtenberger; C Gebhardt; M Hagen; G Keyßer; H-M Lorenz; T Witte
Journal:  Z Rheumatol       Date:  2020-12-02       Impact factor: 1.372
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.